All Stories

  1. Heart rate and blood pressure monitoring in heart failure
  2. Physiological monitoring in the complex multi-morbid heart failure patient - Introduction
  3. Monitoring of biomarkers in heart failure
  4. Clinical case: heart failure and ischaemic heart disease
  5. Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
  6. Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
  7. Correction to: Rosano et al., Cardiovascular disease in women, is it different to men? The role of sex hormones
  8. HFA Congress 2017
  9. Letter to the Editor: “Effects of Testosterone Replacement on Electrocardiographic Parameters in Men: Findings From Two Randomized Trials”
  10. Euro-CVP 2017
  11. The Heart Failure Association Congress confirms itself as the largest European Society of Cardiology sub-speciality congress
  12. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study
  13. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  14. Animal models of cardiac cachexia
  15. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries
  16. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis
  17. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
  18. Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
  19. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study
  20. NSAID position paper
  21. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
  22. Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
  23. Bergamot polyphenolic fraction counteracts erectile dysfunction occurring in patients suffering from type 2 diabetes
  24. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology
  25. Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine
  26. Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance
  27. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure
  28. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension
  29. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone
  30. Safety and efficacy of ezetimibe: A meta-analysis
  31. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease
  32. Mineralocorticoid receptor antagonists, a class beyond spironolactone — Focus on the special pharmacologic properties of eplerenone
  33. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF)
  34. Disclosure of negative trial results. A call for action
  35. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints
  36. Metabolic approach to heart failure: The role of metabolic modulators
  37. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database
  38. Comorbidities Frequency in Takotsubo Syndrome: An International Collaborative Systematic Review Including 1109 Patients
  39. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1
  40. Hypertension: Should we ablate all hypertensives? Pro
  41. Innovative therapeutic approaches for the treatment of myocardial ischemia and angina
  42. Transparency in medical research: Time for a paradigm shift
  43. Innovative therapeutic approaches for the treatment of myocardial ischemia and angina
  44. The Reply
  45. Adaptive licensing — A way forward in the approval process of new therapeutic agents in Europe
  46. A way forward to the elimination of conflict of interest for experts involved in regulatory medicine and guidelines
  47. Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy
  48. Testosterone in men with hypogonadism and high cardiovascular risk, Pros
  49. EFFICACY AND SAFETY OF NOVEL ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE: A META-ANALYSIS OF PHASE III CLINICAL TRIALS
  50. Site selection for heart failure clinical trials in the USA
  51. Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium
  52. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis
  53. Transparency in medical research: Time for a paradigm shift
  54. Steps forward in regulatory pathways for acute and chronic heart failure
  55. Ranolazine
  56. Foreword
  57. Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective
  58. Back to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure
  59. Adaptive licensing — A way forward in the approval process of new therapeutic agents in Europe
  60. Need for gender-specific pre-analytical testing: The dark side of the moon in laboratory testing
  61. Steps forward in regulatory pathways for acute and chronic heart failure
  62. The challenge of performing effective medical research in the era of healthcare data protection
  63. Mineralocorticoid receptor in adipocytes and macrophages: A promising target to fight metabolic syndrome
  64. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
  65. Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials
  66. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysis
  67. Target Organ Damage and RAAS Blockade
  68. Validation of rate of perceived exertion-based exercise training in patients with heart failure: Insights from autonomic nervous system adaptations
  69. Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries
  70. Clinical utility of ivabradine in cardiovascular disease management: current status
  71. Takotsubo Syndrome (Stress Cardiomyopathy): An Intriguing Clinical Condition in Search of Its Identity
  72. Exercise-Induced Skeletal Muscle Remodeling and Metabolic Adaptation: Redox Signaling and Role of Autophagy
  73. Intensive cardiac rehabilitation improves glucometabolic state of non-diabetic patients with recent coronary artery bypass grafting
  74. Developing Therapies for Heart Failure With Preserved Ejection Fraction
  75. A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
  76. Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials
  77. Muscle wasting disease: a proposal for a new disease classification
  78. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy—The PEARL randomized cross-over study
  79. Three-Year Results of Repaired Barlow Mitral Valves via Right Minithoracotomy versus Median Sternotomy in a Randomized Trial
  80. Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy
  81. A statement on ethical standards in publishing scientific articles in the International Journal of Cardiology family of journals
  82. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties
  83. Evaluating the metabolic approach to treatment of diabetic coronary patients
  84. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis
  85. Cardiovascular benefits of HRT may differ by patient age
  86. Increased plasma homocysteine predicts arrhythmia recurrence after minimally invasive epicardial ablation for nonvalvular atrial fibrillation
  87. Tricuspid annular plane systolic excursion is related to performance at six minute walking test in patients with heart failure undergoing exercise training
  88. Anticoagulation in “real world” patients with atrial fibrillation in Italy: Results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study
  89. On-target antihypertensive treatment in Italy: The ISPIT (Indagine Sicoa Paziente Iperteso a Target) survey study
  90. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
  91. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes
  92. Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients
  93. Matched dose interval and continuous exercise training induce similar cardiorespiratory and metabolic adaptations in patients with heart failure
  94. Role of mineralocorticoid receptor and renin–angiotensin–aldosterone system in adipocyte dysfunction and obesity
  95. Severity of left ventricular dysfunction in heart failure patients affects the degree of serum-induced cardiomyocyte apoptosis. Importance of inflammatory response and metabolism
  96. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina — The VASCO-angina study
  97. The heart and the gut
  98. Effect of High-Intensity interval training versus moderate continuous training on 24-h blood pressure profile and insulin resistance in patients with chronic heart failure
  99. Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes
  100. Dose–response relationship of baroreflex sensitivity and heart rate variability to individually-tailored exercise training in patients with heart failure
  101. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study
  102. A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure
  103. Endothelial Progenitor Cells Predict Long-Term Prognosis in Patients With Stable Angina Treated With Percutaneous Coronary Intervention
  104. Endogenous sex hormones are associated with blood pressure change and hypertension incidence in postmenopausal women
  105. Sex Differences in Drug Effects: Interaction with Sex Hormones in Adult Life
  106. Regulation of collateral blood vessel development by the innate and adaptive immune system
  107. Effect of Partial Fatty Acids Oxidation Inhibition With Trimetazidine on Mortality and Morbility in Heart Failure: Results from an International Multicentre Retrospective Cohort Study
  108. Cell Surface Estrogen Receptor Alpha Is Upregulated during Subchronic Metabolic Stress and Inhibits Neuronal Cell Degeneration
  109. Testosterone and heart failure
  110. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention
  111. Effects of a short-term exercise training on serum factors involved in ventricular remodelling in chronic heart failure patients
  112. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism
  113. Editorial Vitamin D: a novel player in endothelial function and dysfunction
  114. Exogenous Testosterone, Cardiovascular Events, and Cardiovascular Risk Factors in Elderly Men: A Review of Trial Data
  115. Oral contraceptives modify DNA methylation and monocyte-derived macrophage function
  116. Androgens and Adipose Tissue in Males: A Complex and Reciprocal Interplay
  117. Comparison of Microlife BP A200 Plus and Omron M6 Blood Pressure Monitors to Detect Atrial Fibrillation in Hypertensive Patients
  118. Gender Disparity in Susceptibility to Oxidative Stress and Apoptosis Induced by Autoantibodies Specific to RLIP76 in Vascular Cells
  119. Optimization of Cardiac Metabolism in Heart Failure
  120. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
  121. A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics
  122. Pharmacokinetics and Pharmacodynamics: The Role of Sex and Gender
  123. Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?
  124. Comparative Long Term Effects of Nebivolol and Carvedilol in Hypertensive Heart Failure Patients
  125. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)
  126. Biomarkers for predicting postmenopausal coronary heart disease
  127. Sarcopenia With Limited Mobility: An International Consensus
  128. Exercise training reduces serum capacity to induce endothelial cell death in patients with chronic heart failure
  129. Effect of lysine hyaluronate on the healing of decubitus ulcers in rehabilitation patients
  130. Editorial [Hot Topic: Gender Differences in Cardiovascular Diseases. A Need for Action (Executive Guest Editors: Giuseppe Barbaro and Giuseppe M.C. Rosano)]
  131. Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
  132. Hydrotherapy added to endurance training versus endurance training alone in elderly patients with chronic heart failure: A randomized pilot study
  133. Trimetazidine improves exercise performance in patients with peripheral arterial disease
  134. Exposure to Phosphodiesterase Type 5 Inhibitors Stimulates Aromatase Expression in Human Adipocytes in vitro
  135. Thrombophilic screening in young patients (<40years) with idiopathic ischemic stroke: A controlled study
  136. Sildenafil Reduces Insulin-Resistance in Human Endothelial Cells
  137. Comparison of Effectiveness of Carvedilol Versus Bisoprolol for Prevention of Postdischarge Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Heart Failure
  138. Tai Chi Enhances the Effects of Endurance Training in the Rehabilitation of Elderly Patients with Chronic Heart Failure
  139. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)
  140. Gender differences in treatment of cardiovascular disease: a task force on gender of the ESC proposal on gender specific studies in cardiovascular pharmacology
  141. With reference to hydrotherapy to heart failure patients
  142. Erratum: Cellular models for understanding adipogenesis, adipose dysfunction and obesity
  143. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression
  144. Testosterone Therapy in Women With Chronic Heart Failure
  145. Effects of Testosterone Undecanoate on Cardiovascular Risk Factors and Atherosclerosis in Middle-Aged Men with Late-Onset Hypogonadism and Metabolic Syndrome: Results from a 24-month, Randomized, Double-Blind, Placebo-Controlled Study
  146. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients
  147. Gender-specific aspects of treatment of cardiovascular risk factors in primary and secondary prevention
  148. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease
  149. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: A randomized, double-blind, placebo-controlled study
  150. C-reactive protein and left atrial appendage velocity are independent determinants of the risk of thrombogenesis in patients with atrial fibrillation
  151. Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study
  152. Reply
  153. Atorvastatin attenuates post-implant tissue degeneration of cardiac prosthetic valve bovine pericardial tissue in a subcutaneous animal model
  154. Cellular models for understanding adipogenesis, adipose dysfunction, and obesity
  155. In uno omnia: Anti-thrombotic agents in challenging comorbidities
  156. Heart rate in ischemic heart disease. The innovation of ivabradine: More than pure heart rate reduction
  157. Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implications
  158. Gender determinants of cardiovascular risk factors and diseases
  159. Role of Endothelial Progenitor Cells in Restenosis and Progression of Coronary Atherosclerosis After Percutaneous Coronary Intervention
  160. Cell survival: is not all about apoptosis
  161. Cell sex determines anoikis resistance in vascular smooth muscle cells
  162. Effect of Antianginal Drugs in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial Infarction
  163. Differential role T helper 1, T helper 2 and CD4+CD25+ regulatory T cells in the development of collateral vessels following induced acute ischemia
  164. Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure
  165. Endothelial progenitor cells in patients with coronary artery disease and left ventricular dysfunction
  166. Metabolic syndrome predicts lower functional recovery in female but not in male patients after an acute cardiac event
  167. Gender differences in the cardiovascular effect of sex hormones
  168. Numbers of endothelial progenitor cells in peripheral blood are similar in younger and older patients with coronary artery disease
  169. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy
  170. Peripheral blood mononuclear cells from mild cognitive impairment patients show deregulation of Bax and Sod1 mRNAs
  171. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women
  172. Cardiovascular aspects of menopausal hormone replacement therapy
  173. Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
  174. The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
  175. Platelet-Derived Growth Factor Receptor β-Subtype Regulates Proliferation and Migration of Gonocytes
  176. Research Resource: Rapid Recruitment of Temporally Distinct Vascular Gene Sets by Estrogen
  177. The Role of Trimetazidine After Acute Myocardial Infarction
  178. Cardiac Metabolism in Myocardial Ischemia
  179. Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
  180. P1-210: Cytokines are not predictive of Alzheimer's disease in patients with mild cognitive impairment
  181. IC-P2-137: Role of leucocyte count and thyroid-stimulating hormone in evolution of mild cognitive impairment to dementia
  182. Metabolic agents in the management of diabetic coronary patients: A new era
  183. Lipids, statins and cardiovascular disease
  184. Corrigendum to ‘‘Acute administration of 17β-estradiol reduces endothelin-1 release during pacing-induced ischemia” [International Journal of Cardiology 116/1 (2007) 34–39]
  185. Short- and long-term outcomes of percutaneous coronary interventions in patients with severe left ventricular dysfunction
  186. Effect of Hormone Therapy on Exercise Capacity in Early Postmenopausal Women
  187. Long-Term Clinical and Angiographic Outcomes of Treatment of Unprotected Left Main Coronary Artery Stenosis With Sirolimus-Eluting Stents
  188. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease
  189. Chronic sildenafil in men with diabetes and erectile dysfunction
  190. Acute administration of 17β-estradiol reduces endothelin-1 release during pacing-induced ischemia
  191. Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women
  192. Menopause and cardiovascular disease: the evidence
  193. The Metabolic Syndrome in Women
  194. Metabolic Therapy for Patients with Diabetes Mellitus and Coronary Artery Disease
  195. Evidence of Cocaine-Related Coronary Atherosclerosis in Young Patients With Myocardial Infarction
  196. Impairment of physical exercise capacity in healthy postmenopausal women
  197. Effect of estradiol 17β upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients
  198. Hypertension in Postmenopausal Women
  199. Hypertension in Postmenopausal Women
  200. Managing cardiovascular risk in menopausal women
  201. Metabolic therapy for the diabetic patients with ischaemic heart disease
  202. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy
  203. Platelet activation status decreases after menopause
  204. Norepinephrine and metaraminol in septic shock: a comparison of the hemodynamic effects
  205. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk
  206. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk
  207. Repercussions of digoxin, digitoxin and estradiol on the endometrial histomorphometry of oophorectomized mice
  208. Postmenopausal hormone replacement therapy increases plasmatic thromboxane β2
  209. Chronic Treatment with Tadalafil Improves Endothelial Function in Men with Increased Cardiovascular Risk
  210. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease
  211. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women
  212. Efeitos agudos dos estrogênios associados a progestogênios sobre a trigliceridemia e reatividade vascular pós-prandial
  213. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk
  214. PLASMA LEVELS OF INFLAMMATORY C-REACTIVE PROTEIN AND INTERLEUKIN-6 PREDICT OUTCOME IN ELDERLY PATIENTS WITH STROKE
  215. Beta-blockers, psychological influences and erectile dysfunction: Reply
  216. Reply: $beta;-Blocker effects on sexual function
  217. 1023-94 Comparative effect of trimetazidine plus sildenafil versus nitrates in the control of myocardial ischemia during sexual activity
  218. 1141-196 Effect of atorvastatin and sildenafil on endothelial function in patients with erectile dysfunction and increased cardiovascular risk
  219. 1001-9 Effect of free fatty acid inhibition on left ventricular function in diabetic patients with coronary artery disease
  220. 1141-194 Chronic therapy with phosphodiesterase 5 inhibitor tadalafil has a sustained effect on endothelial function
  221. Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis
  222. Hormone Replacement Therapy and Cardioprotection
  223. Postmenopausal Hormone Therapy: Lessons from Observational and Randomized Studies
  224. Metabolic and vascular effect of progestins in post-menopausal women
  225. Hormone Replacement Therapy and Cardioprotection
  226. Standard laryngeal Mask Airway™ and LMA-ProSeal™ during laparoscopic surgery
  227. Long‐Term Prognostic Value of Triiodothyronine Concentration in Elderly Patients With Heart Failure
  228. Purpuric gloves and socks syndrome caused by parvovirus B19 infection
  229. Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial
  230. Metformin improves endothelial function in patients with metabolic syndrome X
  231. Plasma levels of inflammatory C-reactive protein and interleukin-6 predict outcome in elderly patients with stroke
  232. Raloxifene effect on endothelial function depends on duration of menopause and previous hormone use
  233. Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels
  234. Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial
  235. Clinical relevance of the HERS trial
  236. Prothrombotic mutations are associated with increased cardiovascular events in postmenopausal women receiving hormone replacement therapy
  237. Different effect of hormone replacement therapy, DHEAS, and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk
  238. Increased C-reactive protein levels in women at increased cardiovascular risk predict one-year events only when associated with increased interleukin-6 levels
  239. Estrogen improves arterial stiffness in postmenopausal diabetic women
  240. Effect of combined hormone replacement therapy on thrombotic and fibrinolytic potentials and Lp(a) levels in elderly women
  241. The differential effects of hormone replacement therapy and selective estrogen receptor modulator on endothelial function seem related to an effect on plasma asymmetric dimethylarginine, an inhibitor of nitric oxide synthase
  242. Continuous 12-lead st-segment monitoring improves identification of low-risk patients with chest pain and a worse in-hospital outcome
  243. A reply
  244. Postmenopausal Women and Cardiovascular Risk: Impact of Hormone Replacement Therapy
  245. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease
  246. Anti-ischemic effect of chronic oestrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes
  247. Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction
  248. Hormone replacement therapy and cardiovascular risk: consistency of results and unreliable data
  249. Hormone replacement therapy: where we stand in Europe
  250. Antianginal and lipid lowering effect of chronic oral androgen supplementation in elderly male patients with coronary heart disease Giuseppe M. C. Rosano, Giuseppe Mercuro, Filippo Leonardo, Sandra Zoncu, Massimo Fini, Daniela Onorati. San Raffaele - R...
  251. Effect of hyperuricoemia upon endothelial function in patients at increased cardiovscular risk Giuseppe M. C. Rosano, Elena Cerquetani, Filippo Leonardo, Massimo Fini, Daniela Onorati. San Raffaele - Roma - TOSINVEST SANITA$prime;, Roma, Italy
  252. Endothelial function and plasma endothelin-1 levels following administration of estradiol valerate and cyproterone acetate in menopausal women at risk for CAD Giuseppe M. C. Rosano, Filippo Leonardo, Giuseppe Mercuro, Sandra Zoncu, Massimo Fini. San Ra...
  253. Effect of lipid lowering therapy with atorvastatin alone or in association with different hormone replacement schemes in female patients with severe hypercholesterolemia Giuseppe M. C. Rosano, Giuseppe Mercuro, Filippo Leonardo, Sandra Zoncu, Massimo F...
  254. The increased plasma levels of C-reactive protein following oral hormone replacement therapy are not related to an increased inflammatory response Giuseppe M. C. Rosano, Otavio Gebara, Massimo Fini, Jos� Aldrighi, Filipo Leonardo, Mauricio Wajngarten, ...
  255. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women
  256. Acute electrophysiologic effect of estradiol 17β in menopausal women
  257. Teratogenic Effects of Antiepileptic Drugs: Use of an International Database on Malformations and Drug Exposure (MADRE)
  258. Cardioprotective effects of ovarian hormones and the HERS in perspective
  259. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system
  260. Recanalization of chronic total coronary occlusions: the impact of a new specific guidewire on primary success rate
  261. Short- and long-term evolution of unstented nonocclusive coronary dissection after coronary angioplasty
  262. The acute effects of sublingual 17β-estradiol on the cardiovascular system
  263. EFFECT OF SILDENAFIL UPON MYOCARDIAL ISCHEMIA IN PATIENTS WITH CHRONIC STABLE ANGINA IN THERAPY WITH BETA-BLOCKERS
  264. Cardiovascular Pharmacology of Hormone Replacement Therapy
  265. Abnormal Autonomic Nervous Control of the Cardiovascular System
  266. Treatment of Patients with Angina and Normal Coronary Arteriograms
  267. Oestrogen improves exercise-induced myocardial ischaemia in women
  268. L-Arginine Improves Endothelial Function in Newly Diagnosed Hypertensives
  269. Effect of Acute Administration of Estradiol 17 Beta on Aortic Blood Flow in Menopausal Women
  270. Effect of Estrogen Replacement Therapy on Heart Rate Variability and Heart Rate in HealthyPostmenopausal Women
  271. Effect of Atenolol on QT Interval and Dispersion in Patients With Syndrome X
  272. A reply
  273. Oestrogen as a calcium channel blocker
  274. Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X
  275. Cyclical variation in paroxysmal supraventricular tachycardia in women
  276. Acute anti-ischemic effect of estradiol 17β in menopausal women with coronary artery disease
  277. Coronary artery occlusion in medically treated patients with unstable angina. The importance of pre-existing coronary artery lesions and response to therapy
  278. Estrogen replacement therapy normalizes the autonomic control of the cardiovascular system in menopausal women
  279. Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction
  280. Estrogen acutely increases peripheral blood flow in postmenopausal women
  281. Effectiveness of prolonged low dose recombinant tissue-type plasminogen activator for refractory unstable angina
  282. Cardiac syndrome X: Clinical characteristics and left ventricular function
  283. 901-8 One-Year Follow-up of Patients Treated with Prolonged Low-dose of rt-PA for Refractory Unstable Angina
  284. 928-81 Importance of Holter Monitoring, as Compared to Exercise Testing, in Revealing ST-segment Changes in Patients with Syndrome X
  285. 976-11 Cyclical Variation in the Occurrence of Paroxysmal Supraventricular Tachycardia in Female Patients
  286. 814-3 Effect of Estradiol-17β upon Coronary Arterial Reactivity to Acetylcholine in Men with Coronary Artery Disease
  287. 901-96 Long Term Evolution of Left Ventricular Function in Patients with Syndrome X
  288. 925-41 Coronary Sinus pH During Dipyridamole Infusion in Patients with Angina and Hypertrophic Cardiomyopathy
  289. Abnormal uptake and washout of thallium-201 in patients with syndrome X and normal-appearing scans
  290. “Syndrome X” as a consequence of acute myocardial infarction
  291. Low formation of nitric oxide in polymorphonuclear cells in unstable angina pectoris
  292. Abnormal autonomic control of the cardiovascular system in syndrome X
  293. Abnormal Neurohumoral Control In Pathogenesis Of Syndrome X
  294. Prearteriolar Coronary Constriction In Pathogenesis Of Syndrome X. Role Of Adenosine
  295. Long-term follow-up of patients initially diagnosed with syndrome X
  296. Intraoperative percutaneous double-balloon valvuloplasty versus surgical commissurotomy for mitral valve stenosis
  297. Angina and normal coronary arteries in women: Gynecologic findings
  298. Chest pain and myocardial ischemia in syndrome X
  299. The ST segment — the herald of ischaemia, the siren of misdiagnosis, or syndrome X?
  300. Unstable angina: Role of silent ischemia and total ischemic time (silent plus painful ischemia), a 6-year follow-up
  301. Coronary artery loops and myocardial ischemia
  302. Estrogen Effect upon Coronary Vasculature